Aims and objectives
Pulmonary metastases occur in approximately 30% of patients dying of cancer.
The 5-years overall survival of patients with pulmonary metastases after complete resection range between 20-40% [5].
One of the reasons for this rather poor survival rate is the high rate of local recurrence in the operated lung (from 43% to 66%) [5].
Poor results of systemic chemotherapy and surgical resection of pulmonary metastases are probably due the inability to achieve effective drug concentrations within the lung [1,
4].
Isolated lung perfusion is a surgical...
Methods and materials
From 2007 to 2014,
74 patients with pulmonary metastases of different types of cancer were included in our study.
14 (18.9%) patients had pulmonary metastases from soft-tissue sarcoma,
13 (17.6%) – colorectal carcinoma,
11 (14.9%) patients - osteosarcoma,
8 (10.8%) - kidney,
4 (5.4%) – breast cancer,
3 (4.1%) – melanoma,
21 (28.3%) – other.
101 isolated lung perfusion procedures were performed.
If bilateral disease was present (43 (58.1%) patients),
a staged bilateral thoracotomy took place within a period of 6-24 weeks.
All 101 isolated...
Results
Pulmonary edema detected after 31 (30.7%) procedures and was unilateral (100%) (fig.
1,
fig.
2).
Pulmonary edema was more often detected after isolated lung perfusion with cisplatin than with melphalan (p < 0.005); pulmonary edema was detected in 7 cases after isolated lung perfusion with melphalan and 24 cases after isolated lung perfusion with cisplatin.
We identified 3 types of pulmonary edema after isolated lung perfusion: interstitial edema,
mixed edema,
alveolar edema.
Interstitial edema was detected after 9 (29.0%) procedures and manifested itself in interlobular...
Conclusion
Pulmonary edema is a frequent complication after isolated lung perfusion.
The most common manifestation of pulmonary edema is mixed edema.
References
1.
Burt M.
Isolated lung perfusion for patients with unresectable metastases from sarcoma: a phase I trial.
The Annals of Thoracic Surgery 2000; 69:1542–1549.
2.
Cypel M.,
Keshavjee Sh.
Isolated lung perfusion.
Frontiers in Bioscience 2012; 4:2226-2232.
3.
Hendriks J.M.,
Grootenboers M.J.,
Schramel F.M.
et.
Isolated lung perfusion with melphalan for resectable lung metastases: a phase I clinical trial.
The Annals of Thoracic Surgery 2004; 6:1919-1926.
4.
Hengst W.A.,
Hendriks J.M.,
Balduyck B.
et al.
Phase II multicenter clinical trial of pulmonary metastasectomy and isolated...